



Biotech Daily

Tuesday January 18, 2011

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: ANTISENSE UP 14%; PHYLOGICA DOWN 9%**
- * **NUSEP SHARE PLAN RAISES \$1m**
- * **NARHEX COMPLETES DOCA, DIRECTORS CHANGE; TO RAISE \$2.5m**
- * **AUSTRALIA TELLS RESONANCE TO REAPPLY FOR FERRISCAN FUNDING**
- * **UBS TAKES 6.5% OF CBIO**

MARKET REPORT

The Australian stock market climbed 0.8 percent on Tuesday January 18, 2011 with the S&P ASX 200 up 38.7 points to 4801.8 points.

Seventeen of the Biotech Daily Top 40 stocks were up, 13 fell, six traded unchanged and four were untraded.

Antisense was best, up 0.1 cents or 14.3 percent to 0.8 cents with 312,500 shares traded, followed by Prana up 11.5 percent to 14.5 cents, with 243,860 shares traded.

Chemgenex and Compumedics both climbed 6.25 percent; Genera and Phosphagenics were up four percent or more; Benitec, Living Cell, Universal Biosensors, Uscom and Virax were up more than three percent; Bionomics, Biota, CSL, Impedimed, Pharmaxis and Prima rose two percent or more; with Starpharma up 1.2 percent.

Phylogica led the falls, down 0.7 cents or 8.75 percent to 7.3 cents with 1.8 million shares traded.

Cellmid lost 5.4 percent with 4.4 million shares traded; Genetic Technologies and Patrys fell four percent or more; Alchemia, Circadian, Cochlear and QRX shed more than two percent; with Nanosonics, Optiscan and Resmed down more than one percent.

NUSEP

Nusep says its oversubscribed share purchase plan at 21 cents a share raised \$1 million. Nusep said all successful applications would receive one listed option, exercisable at 35 cents each, for every three new shares acquired in the share plan.

The company said the options were subject to shareholder approval and applicants not selling any of their shares prior to February 28, 2011.

Nusep said that due to the oversubscription certain applications were rejected and refund cheques would be posted this week.

The company said that the funds would be used to fund its commitment to Singapharm and for working capital (BD: Nov 25, 29, 2010).

Nusep fell two cents or 8.7 percent to 21 cents.

NARHEX LIFE SCIENCES

Narhex has completed its deed of company arrangement, replaced directors Ian Reynolds and Anthony Say with Simon Lill and Peter Christie and hopes to raise \$2.5 million.

Trident Capital's Simon Lill told Biotech Daily that directors David Mandel and Peter Nash would continue.

Mr Lill said the company hoped to raise \$2.5 million thorough the issue of shares at one cent each.

In an announcement to the ASX, Narhex said Nicki Farley had resigned as joint company secretary.

The company said its registered office and business address had changed to Level 24, 44 St George's Terrace, Perth.

Narhex is in a suspension and last traded at 1.6 cents.

RESONANCE HEALTH

Resonance says Australia's Department of Health and Ageing has recommended reapplying for public funding for the Ferriscan iron monitoring diagnostic.

Resonance said the Department of Health and Ageing's medical services advisory committee [MSAC] declined to provide funding for Ferriscan on the existing application but encouraged the company to submit a new condensed application to address specific information requirements.

The company said it would collect and resubmit the additional information by July 2011.

Resonance said Ferriscan was a magnetic resonance imaging test providing an accurate assessment of iron overload and was used in Australia to optimize iron chelation therapy, a treatment used to remove excess iron from the body which results from regular blood transfusions.

The company said Ferriscan was also used to assist in the management of patients with hereditary haemochromatosis.

Resonance said the diagnostic received public funding "in several international jurisdictions and this response from MSAC is disappointing and a setback for patients with iron overload in Australia".

The company said it was progressing US insurance funding.

Resonance said that meetings with private insurance payers were planned for the first three months of 2011.

Resonance was untraded at 1.6 cents.

CBIO

UBS AG and related parties have become substantial shareholders in CBio with the acquisition of 9,202,655 shares or 6.47 percent of the company.

The initial substantial shareholder notice from Hong Kong said UBS AG London and Australia and UBS Securities Australia had acquired shares in relation to a prime broker agreement.

The notice said the most recent purchase was 4,300,000 shares for \$946,000 or 22 cents a share on January 13, 2011.

CBio was up five cents or 21.3 percent to 28.5 cents.